Free tool
FAERS Monitor: Atralin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022070 or its brand name (Atralin, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
6,575
Serious
4,123
63% of reports
Hospitalization
1,418
Death reported
851
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use879
- drug ineffective733
- pain490
- product use in unapproved indication484
- vomiting452
- paraesthesia373
- abdominal pain upper369
- rash364
- nausea355
- diarrhoea348
- headache338
- maternal exposure during pregnancy338
- taste disorder332
- drug intolerance327
- gastrooesophageal reflux disease327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 31 |
| 2006 | 24 |
| 2007 | 39 |
| 2008 | 115 |
| 2009 | 72 |
| 2010 | 78 |
| 2011 | 91 |
| 2012 | 153 |
| 2013 | 101 |
| 2014 | 155 |
| 2015 | 233 |
| 2016 | 354 |
| 2017 | 350 |
| 2018 | 460 |
| 2019 | 353 |
| 2020 | 376 |
| 2021 | 428 |
| 2022 | 512 |
| 2023 | 568 |
| 2024 | 674 |
| 2025 | 809 |
| 2026 | 562 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,584 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 332 | 53.2 | 47.9 | 16,692 |
| gastrooesophageal reflux diseaseSignal | 327 | 13.0 | 11.7 | 3,623 |
| maternal exposure during pregnancySignal | 338 | 12.2 | 11.0 | 3,457 |
| drug intoleranceSignal | 327 | 10.9 | 9.8 | 2,922 |
| paraesthesiaSignal | 373 | 7.6 | 6.9 | 2,142 |
| product use in unapproved indicationSignal | 484 | 6.3 | 5.7 | 2,154 |
| abdominal pain upperSignal | 369 | 5.7 | 5.2 | 1,452 |
| off label useSignal | 879 | 3.2 | 3.0 | 1,395 |
| vomitingSignal | 452 | 3.1 | 2.8 | 646 |
| rashSignal | 364 | 2.7 | 2.4 | 387 |
| painSignal | 490 | 2.6 | 2.3 | 475 |
| drug ineffective | 733 | 1.8 | 1.7 | 266 |
| diarrhoea | 348 | 1.7 | 1.6 | 109 |
| headache | 338 | 1.7 | 1.6 | 105 |
| nausea | 355 | 1.4 | 1.3 | 48 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.